Dordaviprone (Modeyso – Jazz), an oral protease activator, has received accelerated approval from the FDA for treatment of diffuse midline gliomas harboring a H3 K27M mutation in patients ≥1 year old who had disease progression following prior treatment. It is the first drug to be approved in the US for this indication.